[Elucidation of the pathogenesis and treatment of acute myeloid leukemia in animal models]

Acute myeloid leukemia (AML) is a heterogeneous cell population comprising genetically diverse sub-clones with significant differences in properties that vary from one patient to another. Since AML properties are similar to those of hematopoietic stem and myeloid cells, bone marrow as an organ responsible for the survival of AML-initiating cells has been proposed to be able to cause relapse following chemotherapy. Therefore, establishing in vivo experimental systems is critical for understanding the properties of AML cells and developing therapeutic strategies. In this review, the history, advantages, and disadvantages of mouse leukemia models wherein mouse cells are transformed by oncogenic events, including xenograft mice in which human AML cells are transplanted into immunodeficient mice, were introduced. Following which I described the development of chimeric antigen receptor cell therapy using human cytokines expressing the AML xenograft mice.